Download biomedica product list
Testing for Lyme Borreliosis
Lyme disease, also known as Lyme borreliosis, is a tick-borne infectious disease mainly caused by the bacterium species Borrelia burgdorferi.
The disease is primarily transmitted to humans through tick bites. Skin rash, fever, headache, fatigue, and joint pain are among the symptoms characterized by the disease. If left untreated, the infection can lead to more severe conditions and can spread to various parts of the body, affecting joint, heart, and nervous system. Lyme disease is most prevalent in temperate regions, particularly in North America, Europe, and parts of Asia. The incidence of Lyme disease has been increasing in recent years, making it an important health concern.
Early diagnosis and treatment are essential for managing Lyme disease effectively.
Testing for Lyme Borreliosis
The BIOMEDICA Borrelia ELISA kits were utilized in a recent study analyzing antibody patterns that could be useful in guiding the diagnostic schedule: Testing for Lyme borreliosis: could serology tell more? Zóka A et al., J Immunol Clin Microbiol. 2020; 5(3): 85-93. link .
BORRELIA Enzyme immunoassays utilizing antigens produced by recombinant techniques for the detection of IgG and IgM antibodies against the immunodominent antigens of the three genospecies:
Borrelia burgdorferi sensu stricto, Borrelia afzelii and Borrelia garinii
Recombinant Antigens– therefore:
- High sensitivity and specificity confirmed by clinical samples
- Standardized CSF and serum analysis available
- For manual and automated testing
- Widely cited
Lyme borreliosis is a bacterial infection caused by the spirochaete Borrelia burgdorferi, afzellii or garinii, and is characterised by a variety of clinical symptoms.
Lyme borreliosis can be divided into 3 stages:
Stage 1, early dermatitis, Clinical: erythema migrans.
Stage 2, early disseminated infection, Clinical: lymphocytic meningoradiculitis (Bannwarth’s syndrome), neuroborreliosis.
Stage 3, late disseminated infection, Clinical: chronic progressive encephalomyelitis, acrodermatitis chronica atrophicans (ACA), chronic arthritis.
To improve the diagnostic specifity, the Biomedica Borrelia IgG ELISA microwell strips are coated with the following recombinant antigens:
- p21 = OspC (outer surface protein C): B. burgdorferi sensu stricto (B31), B. garinii (20047)
- p18: B. afzelii (pKo)
- p100: B. afzelii (pKo)
- VIsE: fusion protein of different Borrelia genospecies
Recombinant Antigens– therefore:
- No extra RF stripping necessary
- High sensitivity and specificity confirmed by clinical samples
- Standardized CSF-serum-analysis available
- For manual and automated testing
- Widely cited
To improve the diagnostic specifity, the Biomedica Borrelia IgM ELISA microwell strips are coated with the following recombinant antigens:
- p21 = OspC (outer surface protein C): B. afzellii (pKo)
- p21 = OspC (outer surface protein C): B. garinii (20047)
- p41/I = (inner part of flagellin): B. bavariensis (pBi)
- VIsE: fusion proteins of different Borrelia genospecies
Related publications
Lyme borreliosis diagnosis: state of the art of improvements and innovations. Guérin M, Shawky M, Zedan A, Octave S, Avalle B, Maffucci I, Padiolleau-Lefèvre S. BMC Microbiol. 2023 Aug 1;23(1):204. doi: 10.1186/s12866-023-02935-5. PMID: 37528399; PMCID: PMC10392007.
The Epidemiology of Lyme Borreliosis in Europe: An Updated Review on a Growing Public Health Issue. Stark JH, Pilz A, Jodar L, Moïsi JC.Vector Borne Zoonotic Dis. 2023 Apr;23(4):139-141. doi: 10.1089/vbz.2022.0068. Epub 2023 Jan 27. PMID: 37071398; PMCID: PMC10122224.
Effectiveness of personal protection measures against Lyme disease: A review of epidemiologic studies from the United States. Schwartz AM, Mackeprang JM, Mead PS, Hinckley AF. Zoonoses Public Health. 2022 Nov;69(7):777-791. doi: 10.1111/zph.12984. Epub 2022 Jul 5. PMID: 35791092.